KBC Securities

RSS Feed

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Sharad Kumar S.P
  • Wim Lewi
GIMB GIMV NV
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
15h / 25m 15h / 25m 1 EN
Sharad Kumar S.P
  • Sharad Kumar S.P
PREMIUM
GIMB GIMV NV

Gimv 1H24/25 Results: Preparations For A Potential Rights Issue

In its 1H24/25 press release, Gimv announced it is preparing for a potential capital increase (rights issue) over the coming months. A CMD on 22/01/25 will provide more details about its new strategy linked to this transaction. Over 1H24/25, the NAV rose by 9.4% to €55.6 while the overall portfolio's value hit a record high of >€1.7b. Portfolio result came in at €186.8m, a portfolio return of 12.0%. Net result clocked in at €144.9m (€5.1ps), a net return of 9.7%. Portfolio companies posted an ov...

15h / 47m 15h / 47m 1 EN
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thomas Vranken
  • Wim Lewi
UCB UCB S.A.
GIMB GIMV NV
IBAB ION BEAM APPLICATIONS SA
ARGX ARGEN-X SE
CTPNV CTP NV
11/20/24 November 20, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
PREMIUM
UCB UCB S.A.

UCB FIRST LOOK: FDA gives 5/5 with Bimzelx' new approval in HS

UCB has received a 5th nod for Bimzelx as hidradenitis suppurativa joins the fray of approved indications. We see an important role for Bimzelx in this emerging disease space with clear potential to become standard of care over time given its clear outperformance over Novartis' Cosentyx in the clinic. We reiterate our € 173 TP and Accumulate rating.

11/20/24 November 20, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
PREMIUM
ARGX ARGEN-X SE

argenx Myositis go & model update

argenx announced that it is advancing clinical development of SC efgar in idiopathic inflammatory myopathies (myositis). The ongoing seamless Ph2/3 study is a basket trial across three myositis subsets, IMNM, ASyS and DM, each of which will continue into the Ph3 part. Furthermore, following the strong Q3 update, we have adjusted our model to reflect the sustained strong commercial uptake for Vyvgart in myasthenia gravis (MG), as well as the solid start in CIDP. On the other hand, we have removed...

11/20/24 November 20, 2024 1 EN
Alan Vandenberghe ... (+2)
  • Alan Vandenberghe
  • Thomas Couvreur
PREMIUM
BFIT BASIC-FIT NV
SBMO SBM OFFSHORE NV ... (+19)

RISING INTEREST RATES: FEAR OR PRAISE? Thematic Report

Rising interest rates are becoming a hot topic, triggered by a significant uptick in US 10-year treasury yields through February and March. In this note we revisit this topic from several angles. We dig into the empirical side of what we can reasonably expect from the market as a whole when interest rates start to rise. Secondly we review our coverage, putting forward a number of impacted sectors and stocks.

BFIT BASIC-FIT NV
SBMO SBM OFFSHORE NV
MTLS MATERIALISE ADS
EURN EURONAV NV
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
AKA AKKA TECHNOLOGIES SE
BAR BARCO NV
PNL POSTNL NV
DIE D'IETEREN SA
SOF SOFINA SA
GIMB GIMV NV
AGFB AGFA-GEVAERT NV
ONTEX ONTEX GROUP N.V.
BREB BREDERODE S.A.
INGA ING GROEP NV
ASML ASML HOLDING NV
1PG 1-PAGE LIMITED
ADYEN ADYEN NV
XFAB X FAB SILICON FOUNDRIES SE
03/31/21 March 31, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch